Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2091 to 2100 of 2607 total matches.
Hyaluronan Injections for Osteoarthritis of the Knee
The Medical Letter on Drugs and Therapeutics • Jul 03, 1998 (Issue 1030)
injections in decreasing pain both on movement and at
rest (EM Corrado et al, Eur J Rheumatol Inflamm, 15:1 ...
Sodium hyaluronate (Hyalgan - Sanofi) and hylan G-F 20 (Synvisc - Wyeth- Ayerst) have been approved by the FDA for intra-articular injections in patients with knee pain due to osteoarthritis. Hylan G-F 20 is a cross-linked derivative of hyaluronic acid with a higher molecular weight than sodium hyaluronate. 'Hyaluronan' refers to either the acid or its salt.
Phenylpropanolamine and Other OTC Alpha-Adrenergic Agonists
The Medical Letter on Drugs and Therapeutics • Dec 11, 2000 (Issue 1094)
to THE MEDICAL LETTER at 1000 Main Street, New Rochelle, NY
10801-7537. Subscription fees: 1 year, $55.00; 2 ...
The US Food and Drug Administration has ordered removal of phenylpropanolamine from over-the-counter cold remedies and weight loss aids. The FDA based its decision on a recent study showing an increased risk of hemorrhagic stroke in young women taking the drug.
Prozac Weekly
The Medical Letter on Drugs and Therapeutics • Apr 02, 2001 (Issue 1101)
. Subscription fees: 1 year, $55.00; 2 years, $94.00; 3 years, $132.00 ($27.50—U.S. Funds—per year for individual ...
The FDA has approved a new formulation of fluoxetine for once-weekly maintenance treatment of depression in patients who have responded to daily fluoxetine (Prozac).
What is Going on with Levothyroxine
The Medical Letter on Drugs and Therapeutics • Jul 09, 2001 (Issue 1108)
10801-7537. Subscription fees: 1 year, $55.00; 2 years, $94.00; 3 years, $132.00 ($27.50—U.S. Funds—per ...
The media recently reported that the FDA has threatened to withdraw Synthroid from the market, alarming many physicians and patients.
Spinal Manipulation
The Medical Letter on Drugs and Therapeutics • May 27, 2002 (Issue 1131)
-7537
Customer Service:
Toll-free: 1-800-211-2769
Fax: 1-914-632-1733
Web Site: http ...
Spinal manipulation has been used to treat not only back and neck pain, but also many other conditions. A recent commentary questioned its safety.
In Brief: Cetirizine OTC
The Medical Letter on Drugs and Therapeutics • Jan 14, 2008 (Issue 1277)
FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS
1
The Medical ...
Cetirizine (Zyrtec, and others) and cetirizine/pseudoephedrine (Zyrtec-D) are becoming available without a prescription this month for treatment of allergic rhinitis and urticaria in adults and children. Cetirizine is the second of the second-generation H1-antihistamines to become available over the counter. Loratadine (Claritin, and others) was the first.Cetirizine has been shown to be more effective than loratadine in suppressing histamine-induced wheals in healthy volunteers (W Carey et al. Drugs Exp Clin Res 2002; 28:243), but no well-controlled clinical trials have established that any...
A Reminder: Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Jul 28, 2008 (Issue 1291)
freshmen living in dormitories.
1,2
The peak incidence of meningococcal disease, after
early childhood ...
The U.S. Advisory Committee on Immunization Practices has recommended administration of the quadrivalent conjugated polysaccharide meningococcal vaccine (Menactra – Sanofi Pasteur) to all persons 11 to 18 years old, particularly those entering high school and college freshmen living in dormitories.1,2 The peak incidence of meningococcal disease, after early childhood, occurs in the 15-19 year-old age group. The conjugate vaccine is more immunogenic than the meningococcal capsular polysaccharide vaccine (Menommune – Sanofi Pasteur).ADVERSE EFFECTS — The most common adverse reactions with...
In Brief: Exenatide (Byetta) and Pancreatitis
The Medical Letter on Drugs and Therapeutics • Sep 08, 2008 (Issue 1294)
in patients taking exenatide than in patients with
diabetes not taking exenatide is not clear.
1
Given ...
The FDA has issued an update (August 18, 2008; www.fda.gov) on occurrences of acute pancreatitis in patients with diabetes taking exenatide (Byetta – Amylin/Lilly). The latest update, which follows an FDA Alert in October 2007, reports 6 cases of hemorrhagic or necrotizing pancreatitis with 2 deaths in patients taking the drug. Whether pancreatitis occurs more often in patients taking exenatide than in patients with diabetes not taking exenatide is not clear.1Given by subcutaneous injection, exenatide is a synthetic peptide that stimulates release of insulin from pancreatic beta cells.2 It...
Correction: CT Colonography
The Medical Letter on Drugs and Therapeutics • Jan 12, 2009 (Issue 1303)
Colonography (Med Lett Drugs Ther
2008; 50:94)
In Table 1, “Invasive” should be “less” and “more” rather ...
(Med Lett Drugs Ther 2008; 50:94) In Table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively. In the conclusion, CT colonography should be changed to "less invasive" rather than "noninvasive".
Corrections: Biannual IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis and Golimumab (Simponi) for Inflammatory Arthritis
The Medical Letter on Drugs and Therapeutics • Jul 27, 2009 (Issue 1317)
.
Golimumab (Simponi) for Inflammatory Arthritis (Med
Lett Drugs Ther 2009; 51:55)
In Table 1 on page 55 ...
Corrections: Biannual IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis (Med Lett Drugs Ther 2009; 51:49) - The first word of the title should have been Biennial, not Biannual.
Golimumab (Simponi) for Inflammatory Arthritis (Med Lett Drugs Ther 2009; 51:55) - In Table 1 on page 55, the price for certolizumab (Cimzia) should have been $1,341.68 (not $3,136.40).
Golimumab (Simponi) for Inflammatory Arthritis (Med Lett Drugs Ther 2009; 51:55) - In Table 1 on page 55, the price for certolizumab (Cimzia) should have been $1,341.68 (not $3,136.40).